PP405 vs. NOVOGRO™: Why the Hair-Loss “Breakthrough” Story May Be Too Simple

Hair loss is no longer a quiet insecurity people hide under hats. It affects up to about 50% of males and females, and in men it becomes more common with age.

The market tells the same story. For decades, the actual innovation has been embarrassingly thin, the industry still leans heavily on two old pillars: minoxidil and finasteride. Minoxidil likely helps some users keep hairs in the growth phase longer. Finasteride lowers DHT, the major cause of male pattern hair loss. But both bring side effects and neither represents a modern understanding of the whole follicle.

That is why PP405 has generated so much attention. It is one of the few truly new scientific stories in hair loss: a topical drug candidate from Pelage Pharmaceuticals designed to activate dormant hair follicle cells. The other new direction is what NOVOGRO™ are building. But our thesis is different from the PP405 hype: hair loss is not a one-switch problem, so it probably will not be solved by a one-switch product.

What PP405 Is

PP405 deserves serious attention. This is not another caffeine shampoo with a dramatic label. Pelage Pharmaceuticals has strong academic roots, with technology based on UCLA scientists' discovery of a metabolic switch involved in hair follicle stem-cell activation. Pelage describes PP405 as a non-hormonal topical small molecule intended for all genders, skin types, and hair types.

People have hyped about PP405 for years. But when the promise will be fulfilled remains unknown.

The basic idea is elegant. Hair follicle stem cells have a living cycle. Hair only grows during the growing phase (anagen), and can become dormant. PP405 is designed to wake them up by targeting metabolism. By inhibiting a target called MPC, the follicle is pushed toward activation, accelerating hair-cycle entry.

That is why the market is excited. PP405 is different from finasteride, which brings lots of side effects, or minoxidil, whose mechanism is still unclear. It is trying to do something bolder: reactivate follicles that may still be present but biologically asleep.

Pelage's recent results added fuel to the story.

That is impressive. But it is also not the final word.

The Limitation of the PP405 Approach

Here is the uncomfortable part: PP405 may be exciting, but it still focuses on one main idea.

Hair loss is not caused by just one problem. It is usually the result of many changes happening at the same time. Hormones can affect the follicle. Aging can slow things down. Inflammation, poor scalp environment, stress on the follicle, and weaker support from surrounding cells can all play a role. In common hair loss, the growth phase becomes shorter, follicles become smaller, and hair gradually gets thinner.

That is why "waking up" dormant hair-follicle stem cells is exciting, but it may not be enough by itself. A follicle also needs the right environment to keep growing. It needs healthy support cells, good signaling, enough energy, and long-term conditions that help the hair cycle continue.

There is also a reason to be careful. PP405 works by targeting cell metabolism, and metabolism is powerful biology. When you push a biological system in one direction, there can sometimes be unexpected effects. Some early research has suggested that blocking this type of metabolic pathway in human hair follicles may also create stress in the follicle under certain conditions.

That does not mean PP405 is unsafe or ineffective. It is still an investigational drug, and Pelage has reported encouraging safety results so far. But it does mean people should not treat the phrase "metabolic switch" like magic. Hair loss is complicated. Long-term safety, proper dosing, lasting results, and real-world performance still need to be proven.

People should not treat the phrase "metabolic switch" like magic. Hair loss is complicated.

NOVOGRO™'s Philosophy: Build for the Whole Follicle

The vision for NOVOGRO™ is more ambitious and, frankly, more realistic: the follicle is an ecosystem.

A hair follicle is not just a stem-cell switch. It is a living mini-organ. Dermal papilla cells (hair cells, or DPC) sit at the base of the follicle and help regulate when follicles enter the growing phase, how long they stay active, and how thick the resulting hair becomes. As hair thinning progresses, DPC number and activity can decline, weakening the hair growth. NOVOGRO™ emphasizes DPC proliferation as a direct way to support the cells that drive hair growth, and formulations with NOVOGRO™ showed measurable increases in DPC growth compared with untreated controls and outperformed several leading hair products in side-by-side testing.

That matters because "waking up" a follicle is not enough if the follicle wakes up into a weak environment.

NOVOGRO™ is designed around a broader idea: support the biology around hair growth, not just one mechanism. That includes DPC support, follicle-environment signaling, and practical formulation considerations. The research also describes follicloid testing, where lab-grown follicle-like structures are used to observe hair-growth-related behavior in a more realistic setting. In that model, NOVOGRO™ improved follicloid growth and showed stronger growth than other leading serums tested side by side.

This is the difference between a beautiful mechanism and a complete product philosophy. DPCs are complex entities. A single treatment is not sufficient to reverse hair loss.

PP405 vs. NOVOGRO™: The Real Comparison

PP405 is a single investigational drug candidate. NOVOGRO™ is a multi-active product strategy. PP405 is built around stem-cell activation; NOVOGRO™ 623, 624, and 273 are being developed as active molecules within a broader system for follicle support. That means the comparison is not simply "which molecule is cooler?" It is: do users need one elegant biological trigger, or a product that supports the follicle from multiple angles?

Users dealing with hair thinning now do not live inside a press release. They need practical options.

PP405 has the advantage of formal clinical development. It is moving through the FDA pathway. But PP405 is not available to consumers today. It has been in clinical development since at least 2024. If successful, it may become an important prescription treatment. But users dealing with hair thinning now do not live inside a press release. They need practical options.

RE:YOU, the biology-first serum powered by NOVOGRO™, is building around current-use practicality: active molecules, formulation design, and biological testing that looks beyond a single stem-cell activation claim. The research also highlights a basic but often ignored issue: many serum ingredients degrade under real-world conditions such as air, light, water, and temperature changes, which can reduce effectiveness even when the label still looks good.

This is the part the hair-care industry does not like to admit: a "science-backed" ingredient is not enough. A product has to remain active, reach the right environment, and support the biology that matters.

Why This Matters for Real Users

The PP405 story is exciting because people are desperate for something new. But excitement can become distortion. The public hears "reactivates dormant follicles" and starts imagining a universal baldness reversal product. That is not where the evidence is yet.

Real hair loss is complex. Some follicles may be dormant. Some may be thinning. Some may be affected by stress, inflammation, aging, or poor scalp conditions. A single-mechanism drug may help a subset of users very well. But the broader population likely needs broader support.

That's the whole argument for NOVOGRO™. We're not throwing shade at PP405. we're calling out the idea that the next era of hair growth should ride on one mechanism alone.

RE:YOU's Clinical Trial Data

Talk is cheap. Receipts aren't. So here's where NOVOGRO™ actually has to earn its keep: RE:YOU, the serum built on it, put through a 190-person, double-blinded, randomized trial. RE:YOU went straight at minoxidil, the drug the whole industry still bows to as the gold standard, for 90 straight days. Here's the scorecard.